Skip to search formSkip to main contentSkip to account menu

ABI-009

National Institutes of Health

Related topics

Related topics

1 relation
Nanoparticle Albumin-Bound Rapamycin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
A phase I/II investigation of nivolumab and ABI-009 (nab-sirolimus) in advanced undifferentiated pleomorphic sarcoma (UPS), liposarcoma (LPS), chondrosarcoma (CS), osteosarcoma (OS), and Ewing…
11057 Background: Immune checkpoint inhibitors that promote sustained T cell activation may have synergistic activity with an… 
2019
2019
A phase I/II multicenter study of ABI-009 (nab-sirolimus) combined with FOLFOX and bevacizumab as first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC) with or without…
TPS730 Background: Very few treatment options are available for pts with mCRC beside the standard of care (SOC), 5-FU based… 
2019
2019
Abstract 3896: Distinct pharmacokinetics, tissue distribution and CNS penetration of ABI-009 (nab-Sirolimus)
Background: Activation of the mTOR signaling pathway is frequently observed in multiple types of cancer. The poor solubility and… 
2019
2019
ABI-009, nab-Sirolimus, an mTOR Inhibitor with High Lung Accumulation in Preclinical Models Is Active in Patients with Severe Pulmonary Arterial Hypertension
2019
2019
Initial results of a phase III investigation of safety/efficacy of nivolumab and ABI-009 (nab-sirolimus) in advanced undifferentiated pleomorphic sarcoma (UPS), liposarcoma (LPS), chondrosarcoma (CS…
21 Background: Objectives: (1) To investigate the MTD of ABI-009 when given with nivolumab, a PD-1 inhibitor, in previously… 
2019
2019
PATIENTS WITH SEVERE PULMONARY ARTERIAL HYPERTENSION TREATED WITH ABI-009, NAB-SIROLIMUS, AN MTOR INHIBITOR: INTERIM RESULTS FROM A PHASE 1 CLINICAL TRIAL
2018
2018
Clinical Trials Corner
In this issue, we highlight two trials that rede fi ne the treatment of upper tract urothelial cancer. First, is the OLYMPUS trial… 
2015
2015
A phase I/II multi-center study of intravesical nanoparticle albumin-bound rapamycin (ABI-009) in the treatment of BCG refractory non-muscle invasive bladder cancer.
TPS4576 Background: Inactivation of p53 and PTEN mutations promotes progression in bladder cancer via deregulation of the… 
2009
2009
Combination Regimens ofnab-Rapamycin (ABI-009) Effective Against MDA-MB-231 Breast-Tumor Xenografts.
Background: The mammalian target of Rapamycin (mTOR) is a key intracellular kinase integrating cell proliferation and survival… 
2008
2008
Toxicology and safety pharmacology of nanoparticle albumin-bound (nab) rapamycin (ABI-009)
5732 Background: The mammalian target of rapamycin (mTOR) is involved in the control of cellular growth and proliferation and is… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)